SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has disrupted clinical trials worldwide [1]. This could delay the approval of new medicines and reduce access to investigational treatments via clinical trials. This particularly impacts patients with rare diseases such as cystic fibrosis (CF).

Source: European Respiratory Journal - September 16, 2020 Category: Respiratory Medicine Authors: van Koningsbruggen-Rietschel, S., Dunlevy, F., Bulteel, V., Downey, D. G., Dupont, L. Tags: Original Articles: Correspondence Source Type: research